Please login to the form below

Not currently logged in


This page shows the latest Braftovi news and features for those working in and with pharma, biotech and healthcare.

EORTC and Pierre Fabre launch phase 3 trial for melanoma

EORTC and Pierre Fabre launch phase 3 trial for melanoma

The study – COLUMBUS-AD – will assess whether the combination of BRAF and MEK inhibitors Braftovi (encorafenib) and Mektovi (binimetinib) can prolong recurrence-free survival (RFS) and improve distant metastasis-free survival ... Patients will

Latest news

More from news
Approximately 1 fully matching, plus 4 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Subscribe to our email news alerts

Featured jobs


Add my company
Envision Pharma Group

We are a global leader in the medical affairs space. Our purpose-built software and scientific solutions make us a unique...

Latest intelligence

Our Top 5 Pharma Picks From Cannes Lions
Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
The Evolving Role of the Sales Rep
The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
Measure your omnichannel maturity with our new tool
Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....